News
News Center
2024-08-20
Clinical Recruitment: Patients with Autoimmune Pulmonary Alveolar Proteinosis
A Phase IIa clinical trial investigating the use of human bone marrow mesenchymal stem cells for the treatment of autoimmune alveolar proteinosis is currently underway, conducted jointly by Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. and the Department of Respiratory Medicine at the First Affiliated Hospital of Guangzhou Medical University. The study is actively recruiting patients with autoimmune alveolar proteinosis who are willing to voluntarily participate in this Phase IIa trial.
+
2023-06-07
Recently, Jiuzhitang Maker’s Phase I clinical trial of ischemic tolerance human allogeneic bone marrow mesenchymal stem cells (it-hMSC) for the treatment of ischemic stroke (Approval No.: JXSL1900126) has completed enrollment of all participants and demonstrated a favorable safety profile. Following evaluation by the Center for Drug Evaluation at the National Medical Products Administration, the project has been approved to advance into Phase IIa clinical trials.
+
2024-10-15
Clinical Recruitment: 45 Patients with Ischemic Stroke
Currently, China's first clinical trial (ASSIST) using imported stem cells to treat ischemic stroke—led by Jiuzhitang Maker—is recruiting 45 voluntary participants who have experienced ischemic stroke for its Phase IIa trial.
+
2025-03-12
Jiuzhitang Maker: China's First Clinical Trial Approved for a Stem-Cell Drug Targeting Autism!
Jiuzhitang Maker’s third stem-cell-based new drug has successfully received approval for a clinical trial aimed at treating Autism Spectrum Disorder (ASD). This marks the nation’s first-ever clinical trial using human bone marrow mesenchymal stem cells to treat autism, representing a landmark milestone for Jiuzhitang Maker in the field of regenerative medicine—and underscoring the company’s robust R&D capabilities and promising growth prospects.
+
2025-08-27
China's first! Jiuzhitang Maker's stem-cell drug for autism officially begins clinical trials.
This is Jiuzhitang Maker's third domestically developed Class 1 biologic new drug based on stem cells—and also the first-ever clinical trial in China using human bone marrow-derived mesenchymal stem cells to treat Autism Spectrum Disorder (ASD).
+
2025-09-05
Jiuzhitang Maker: Research-grade Stem Cells—We Sincerely Invite Distributors to Join Us
When pursuing high-quality, reproducible, and translational scientific research, selecting a reliable stem cell supplier is crucial. Jiuzhitang Maker, with its established stem cell production technology and comprehensive stem cell quality management system, provides researchers worldwide with a solid foundation of assurance. Here are several key advantages of Jiuzhitang Maker’s research-grade stem cells:
+
2025-11-10
Jiuzhitang Maker, built on CNAS accreditation as its foundation and guided by pharmaceutical-grade standards, ensures that every test report can withstand rigorous scientific replication and regulatory scrutiny.
+
2025-11-10
As more and more research teams realize that "a stem cell IND application isn’t the end—it’s just the beginning"—China’s stem cell drug development may be reaching a pivotal moment, shifting from "technological catch-up" to "systemic breakthrough." And on this journey toward clinical translation, the value of specialized expertise has never been clearer.
+
2025-08-27
Jiuzhitang MakerCQDMO platform is dedicated to accelerating the entire process—from research and development to market launch—of stem cell therapy products. Leveraging its established stem cell production processes, robust quality management system, and extensive clinical registration expertise, the platform provides a reliable pathway for advancing stem cell IND applications.
+
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy